Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers.
Lee GalmorRinat Bernstein-MolhoMiri Sklair-LevyDana Madoursky-FeldmanDov ZippelYael LaitmanEitan FriedmanPublished in: Breast cancer research and treatment (2020)
RRBM is still infrequently elected by Israeli BRCA1/BRCA2 mutation carriers, with married women with one relative with BC who have not undergone previous breast biopsy more likely to opt for RRBM.